NHS claims that new healthcare innovations delivered under its Innovation and Technology Payment programme have reached 300,000 patients.
Going by an announcement from NHS England chief executive Simon Stevens at the Reform digital health conference in London, an additional 400,000 plus patients are set to benefit in 2019 from new tests, procedures and treatments as part of the NHS Long Term Plan.
Some of the latest healthcare innovations offered by the NHS are a new pre-eclampsia test based on placental growth factor (PIGF) for pregnant women, and Gammacore – a handheld gadget that uses low-levels of electric current to reduce pain caused by cluster headache.
The new treatments and tests are part of the Innovation and Technology Payment programme, which has been designed to accelerate the rollout of latest technology across the UK.
Also included in the latest healthcare innovations of the programme is the high sensitivity troponin test, a new type of blood test to detect changes in protein levels in blood. Through the test, emergency doctors can rule out a heart attack within three hours, thereby helping in quicker treatment and in avoiding hospitalisation.
NHS England said that 10 other new tests and treatments will get funding under the Innovation and Technology Payment programme. Among these is HeartFlow – a computer programme that generates a digital 3D model of the heart which can help in avoiding the need for invasive procedures.
Stevens said: “From improving care for pregnant women to using digital modelling to assess heart conditions and new tests to prevent unnecessary hospitalisations for suspected heart attacks, the NHS is taking action to ensure patients have access to the very best modern technologies. It’s heartening to see the NHS grasping with both hands these rapidly advancing medical innovations.”
According to the NHS, plans to accelerate the uptake of proven, cutting-edge treatments are being monitored by the Accelerated Access Collaborative (AAC).
AAC chief executive and NHS England innovation and life sciences director Sam Roberts said: “This programme has been amazingly successful at getting new tests and treatments to patients, with over 300,000 patients benefitting already, and this year we have another great selection of proven innovations.
“We will build on this success with our commitments set out in the Long Term Plan, to support the latest advances and make it easier for even more patients to benefit from world-class technology.”